Sunesis Pharmaceuticals (SNSS) Shares are Up 0.63%

Sunesis Pharmaceuticals (SNSS) : Traders are bullish on Sunesis Pharmaceuticals (SNSS) as it has outperformed the S&P 500 by a wide margin of 25.12% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 0.2%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 0.63% in the last 1 week, and is up 28.24% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.

Sunesis Pharmaceuticals (NASDAQ:SNSS): The stock opened at $0.67 on Friday but the bulls could not build on the opening and the stock topped out at $0.69 for the day. The stock traded down to $0.65 during the day, due to lack of any buying support eventually closed down at $0.65 with a loss of -3.18% for the day. The stock had closed at $0.68 on the previous day. The total traded volume was 209,162 shares.

The stock has recorded a 20-day Moving Average of 18.45% and the 50-Day Moving Average is 19.76%. Sunesis Pharmaceuticals, Inc. is up 36.59% in the last 3-month period. Year-to-Date the stock performance stands at -27.13%.


Sunesis Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Companys program is QINPREZOTM (vosaroxin), which is its product candidate for the treatment of acute myeloid leukemia (AML). Vosaroxin is an anticancer quinolone derivative (AQD), which is a class of compounds that has not been used previously for the treatment of cancer. Vosaroxin is an AQD, which is used for the treatment of cancer. MLN2480 is an oral, investigative drug selective for pan-Raf kinase inhibition, in patients with relapsed or refractory solid tumors. SNS-062 is a non-covalently binding inhibitor of Brutons tyrosine kinase (BTK). PDK1 is a kinase and mediator of PI3K/AKT signaling, which is a pathway involved in cell growth, differentiation, survival and migration.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.